Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.

MLA

Steppan, Ilona, et al. “Treatment of Recurrent Platinum-Resistant Ovarian Cancer with Pegylated Liposomal Doxorubicin--an Evaluation of the Therapeutic Index with Special Emphasis on Cardiac Toxicity.” Chemotherapy, vol. 55, no. 6, 2009, pp. 391–98. EBSCOhost, https://doi.org/10.1159/000262452.

APA

Steppan, I., Reimer, D., Sevelda, U., Ulmer, H., Marth, C., & Zeimet, A. G. (2009). Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity. Chemotherapy, 55(6), 391–398. https://doi.org/10.1159/000262452

Chicago

Steppan, Ilona, Daniel Reimer, Ursula Sevelda, Hanno Ulmer, Christian Marth, and Alain G Zeimet. 2009. “Treatment of Recurrent Platinum-Resistant Ovarian Cancer with Pegylated Liposomal Doxorubicin--an Evaluation of the Therapeutic Index with Special Emphasis on Cardiac Toxicity.” Chemotherapy 55 (6): 391–98. doi:10.1159/000262452.